HeartLung Technologies, a company based in Houston, has received approval from the U.S. Food and Drug Administration (FDA) for its AI-powered tool called AutoChamber. This software quickly analyzes chest CT scans to find early signs of coronary artery disease (CAD) and other serious heart conditions.
AutoChamber works with various types of chest CT scans, including those done for measuring coronary artery calcium (CAC) or screening for lung cancer. In just 15 to 20 seconds, it generates a report that estimates the size of the patient’s heart chambers and highlights any unusual findings for doctors to review.
AutoChamber can also analyze coronary CT angiography (CCTA) scans, which have become popular for heart assessments. Nathan Wong, a professor of medicine and epidemiology at the University of California, Irvine, says AutoChamber could help find people at higher heart risk from regular CT scans, especially those done for lung cancer screening.
The tool goes beyond just spotting coronary disease. According to Morteza Naghavi, founder of HeartLung Technologies, AutoChamber can also detect risks for heart failure, atrial fibrillation, and stroke.
AutoChamber had previously received a special designation from the FDA as a breakthrough device, which means it was prioritized for a faster approval process due to its high potential to improve health outcomes.
Source: cardiovascularbusiness
